<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01909791</url>
  </required_header>
  <id_info>
    <org_study_id>DRCR.net Protocol V</org_study_id>
    <secondary_id>EY14231</secondary_id>
    <secondary_id>EY23207</secondary_id>
    <secondary_id>EY18817</secondary_id>
    <nct_id>NCT01909791</nct_id>
  </id_info>
  <brief_title>Treatment for CI-DME in Eyes With Very Good VA Study</brief_title>
  <acronym>Protocol V</acronym>
  <official_title>Treatment for Central-Involved Diabetic Macular Edema in Eyes With Very Good Visual Acuity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jaeb Center for Health Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Eye Institute (NEI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Jaeb Center for Health Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although multiple studies have clearly demonstrated that ranibizumab therapy is more
      effective than laser alone for vision gain and avoiding vision loss in patients with
      central-involved Diabetic Macular Edema (DME), only eyes with poor visual acuity, such as a
      visual acuity letter score of 78 or worse (approximate Snellen equivalent of 20/32 or worse)
      were eligible. Eyes that have central-involved DME with &quot;good&quot; visual acuity (20/25 or
      better) have not been addressed systematically by recent studies for treatment of DME.
      Baseline cohort characteristics from the Early Treatment Diabetic Retinopathy Study (ETDRS)
      suggest that a substantial percentage of eyes with central-involved DME may retain good
      vision. The investigators do not know definitively whether eyes with central-involved DME and
      good vision do better with anti-VEGF (vascular endothelial growth factor) (e.g. aflibercept)
      therapy initially, or focal/grid laser treatment or observation initially followed by
      anti-VEGF only if vision worsens.

      The primary objective of the protocol is to compare the % of eyes that have lost at least 5
      letters of visual acuity at 2 years compared with baseline mean visual acuity in eyes with
      central-involved DME and good visual acuity defined as a Snellen equivalent of 20/25 or
      better (electronic-ETDRS letter score of 79 or better) that receive (1) prompt focal/grid
      photocoagulation + deferred anti-VEGF, (2) observation + deferred anti-VEGF, or (3) prompt
      anti-VEGF.

      Secondary objectives include:

        -  Comparing other visual acuity outcomes between treatment groups, such as the percent of
           eyes with at least 5, 10 and 15 letter losses in visual acuity from baseline mean visual
           acuity, percent of eyes with at least 5 letter gain in visual acuity from baseline, mean
           visual acuity, mean change in visual acuity, adjusted for baseline mean visual acuity

        -  For eyes randomized to deferred anti-VEGF, the percentage of eyes needing anti-VEGF
           treatment

        -  Comparing optical coherence tomography (OCT) outcomes, such as the mean change in OCT
           central subfield (CSF) thickness, adjusted for baseline mean thickness

        -  Comparing the number of eyes with PDR at randomization, proportion of eyes avoiding
           vitreous hemorrhage or panretinal photocoagulation (PRP) or vitrectomy for PDR between
           treatment groups

        -  Comparing safety outcomes between treatment groups

        -  Comparing associated treatment and follow-up exam costs between treatment groups
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">September 11, 2018</completion_date>
  <primary_completion_date type="Actual">September 11, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Eyes With at Least 5-letter Decrease in E-ETDRS Visual Acuity Letter Score From Baseline</measure>
    <time_frame>2 years</time_frame>
    <description>Best-corrected visual acuity following protocol-defined refraction. Visual Acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study (E-ETDRS) visual acuity test on a scale from 100 letters (Snellen equivalent of 20/12) to 0 letters (Snellen equivalent of 20/800).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Eyes With at Least 5-letter Increase or at Least 5-, 10-, or 15-letter Decrease in E-ETDRS Visual Acuity Letter Score From Baseline</measure>
    <time_frame>1 year</time_frame>
    <description>Best-corrected visual acuity following protocol-defined refraction. Visual Acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study (E-ETDRS) visual acuity test on a scale from 100 letters (Snellen equivalent of 20/12) to 0 letters (Snellen equivalent of 20/800).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in E-ETDRS Visual Acuity Letter Score From Baseline</measure>
    <time_frame>1 year</time_frame>
    <description>Best-corrected visual acuity following protocol-defined refraction. Visual Acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study (E-ETDRS) visual acuity test on a scale from 100 letters (Snellen equivalent of 20/12) to 0 letters (Snellen equivalent of 20/800).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in E-ETDRS Visual Acuity Letter Score From Baseline Over 2 Years (Area Under the Curve)</measure>
    <time_frame>2 year</time_frame>
    <description>Best-corrected visual acuity following protocol-defined refraction. Visual Acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study (E-ETDRS) visual acuity test on a scale from 100 letters (Snellen equivalent of 20/12) to 0 letters (Snellen equivalent of 20/800). The area under the curve (units = letters·years) was divided by 2 years (units = years) to obtain an average change in letter score (units = letters) over the 2-year follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in OCT Central Subfield Thickness From Baseline</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Eyes With at Least 1 or 2 Logarithmic-step Central Subfield Thickness Improvement and Worsening</measure>
    <time_frame>1 year</time_frame>
    <description>Logarithmic transformation of optical coherence tomography central subfield thickness (CST) is calculated by taking the log base 10 of the ratio of the central subfield thickness divided by 200 and rounding to the nearest hundredth. The change is the change in the log values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Eyes With no Center-involved Diabetic Macular Edema and at Least 10% Central Subfield Thickness Decrease</measure>
    <time_frame>1 year</time_frame>
    <description>Center-involved diabetic macular edema defined as follows by central subfield thickness according to optical coherence tomography machine and sex: Heidelberg Spectralis ≥ 305 µm in women and ≥ 320 µm in men, and Zeiss Cirrus ≥ 290 µm in women and ≥ 305 µm in men.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Number of Intraocular Injections of 2.0-mg Aflibercept Received Per Participant</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Eyes With ≥ 2-step Worsening of Diabetic Retinopathy</measure>
    <time_frame>2 years</time_frame>
    <description>Includes eyes with baseline severity level of 75 (high-risk proliferative diabetic retinopathy) or less based on reading center grading of color fundus photographs using the Early Treatment Diabetic Retinopathy Study severity scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For Eyes Randomized to Initial Laser Photocoagulation and Initial Observation Groups, the Percentage Receiving Aflibercept Treatment</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Eyes With at Least 5-, 10-, or 15-letter Decrease in E-ETDRS Visual Acuity Letter Score From Baseline</measure>
    <time_frame>2 years</time_frame>
    <description>Best-corrected visual acuity following protocol-defined refraction. Visual Acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study (E-ETDRS) visual acuity test on a scale from 100 letters (Snellen equivalent of 20/12) to 0 letters (Snellen equivalent of 20/800).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in E-ETDRS Visual Acuity Letter Score From Baseline</measure>
    <time_frame>2 years</time_frame>
    <description>Best-corrected visual acuity following protocol-defined refraction. Visual Acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study (E-ETDRS) visual acuity test on a scale from 100 letters (Snellen equivalent of 20/12) to 0 letters (Snellen equivalent of 20/800).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in OCT Central Subfield Thickness From Baseline</measure>
    <time_frame>1 year</time_frame>
    <description>Measured using spectral-domain optical coherence tomography (OCT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Eyes With at Least 1 or 2 Logarithmic-step Central Subfield Thickness Improvement and Worsening</measure>
    <time_frame>2 years</time_frame>
    <description>Logarithmic transformation of optical coherence tomography central subfield thickness is calculated by taking the log base 10 of the ratio of the central subfield thickness divided by 200 and rounding to the nearest hundredth. The change is the change in the log values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Eyes With no Center-involved Diabetic Macular Edema and at Least 10% Central Subfield Thickness Decrease</measure>
    <time_frame>2 years</time_frame>
    <description>Center-involved diabetic macular edema defined as follows by central subfield thickness according to optical coherence tomography machine and sex: Heidelberg Spectralis ≥ 305 µm in women and ≥ 320 µm in men, and Zeiss Cirrus ≥ 290 µm in women and ≥ 305 µm in men.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Number of Focal/Grid Photocoagulation Sessions Performed Per Participant</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Eyes With ≥ 2-step Improvement of Diabetic Retinopathy</measure>
    <time_frame>2 years</time_frame>
    <description>Includes eyes with baseline severity level of 35 (mild non-proliferative diabetic retinopathy) or greater based on reading center grading of color fundus photographs using the Early Treatment Diabetic Retinopathy Study severity scale. Excludes eyes with severity level 60 at baseline since improvement is not possible in these eyes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Number of Intraocular Injections of 2.0-mg Aflibercept Received Per Participant</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">702</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>Prompt Laser + Deferred Aflibercept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Focal/grid laser followed by intravitreal aflibercept if vision worsens</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observation + Deferred Aflibercept</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>No treatment to start followed by intravitreal aflibercept if vision worsens (deferred laser may be added to intravitreal aflibercept if certain criteria are met)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prompt Aflibercept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravitreal aflibercept at baseline and every 4 weeks as needed (deferred laser may be added to intravitreal aflibercept if certain criteria are met)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Prompt Laser</intervention_name>
    <description>Focal/grid laser performed at baseline and as needed during follow-up</description>
    <arm_group_label>Prompt Laser + Deferred Aflibercept</arm_group_label>
    <other_name>focal/grid photocoagulation</other_name>
    <other_name>laser treatment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prompt aflibercept</intervention_name>
    <description>Intravitreal injection of 2.0mg aflibercept performed on the day of randomization and up to every 4 weeks using defined treatment criteria</description>
    <arm_group_label>Prompt Aflibercept</arm_group_label>
    <other_name>intravitreal anti-VEGF</other_name>
    <other_name>Eylea</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Deferred laser</intervention_name>
    <description>Focal/grid laser is initiated while receiving anti-VEGF injections only if certain criteria are met</description>
    <arm_group_label>Observation + Deferred Aflibercept</arm_group_label>
    <arm_group_label>Prompt Aflibercept</arm_group_label>
    <other_name>focal/grid photocoagulation</other_name>
    <other_name>laser treatment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Deferred aflibercept</intervention_name>
    <description>Intravitreal injection of 2.0mg aflibercept performed once certain criteria for vision loss are met and then up to every 4 weeks using defined treatment criteria</description>
    <arm_group_label>Observation + Deferred Aflibercept</arm_group_label>
    <arm_group_label>Prompt Laser + Deferred Aflibercept</arm_group_label>
    <other_name>intravitreal anti-VEGF</other_name>
    <other_name>Eylea</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age &gt;= 18 years

          2. Diagnosis of diabetes mellitus (type 1 or type 2)

             Any one of the following will be considered to be sufficient evidence that diabetes is
             present:

               1. Current regular use of insulin for the treatment of diabetes

               2. Current regular use of oral anti-hyperglycemia agents for the treatment of
                  diabetes

               3. Documented diabetes by American Diabetes Association (ADA) and/or World Health
                  Organization (WHO) criteria.

          3. Able and willing to provide informed consent.

        Meets all of the following ocular criteria in at least the one eye:

          1. Best corrected E-ETDRS visual acuity letter score ≥ 79 (approximate Snellen equivalent
             20/25 or better) at two consecutive visits within 1 to 28 days.

          2. On clinical exam, definite retinal thickening due to DME involving the center of the
             macula.

          3. Diabetic macular edema confirmed on OCT (equivalent to CSF thickness on OCT ≥250
             microns on Zeiss Stratus or gender-specific spectral domain OCT equivalent) at two
             consecutive visits within 1 to 28 days.

             (a) Investigator must verify accuracy of OCT scan by ensuring it is centered and of
             adequate quality.

          4. The investigator is comfortable with the eye being randomized to any of the three
             treatment groups (observation, laser, or anti-VEGF initially).

             (a) If focal/grid photocoagulation is contraindicated because all leaking
             microaneurysms are too close to the fovea or the investigator believes the DME that is
             present will not benefit from focal/grid photocoagulation, the eye should not be
             enrolled.

          5. Media clarity, pupillary dilation, and individual cooperation sufficient for adequate
             OCT and fundus photographs.

        Exclusion Criteria:

          1. History of chronic renal failure requiring dialysis or kidney transplant.

          2. A condition that, in the opinion of the investigator, would preclude participation in
             the study (e.g., unstable medical status including blood pressure, cardiovascular
             disease, and glycemic control).

          3. Initiation of intensive insulin treatment (a pump or multiple daily injections) within
             4 months prior to randomization or plans to do so in the next 4 months.

          4. Participation in an investigational trial within 30 days of randomization that
             involved treatment with any drug that has not received regulatory approval for the
             indication being studied.

             (a) Note: study participants cannot receive another investigational drug while
             participating in the study.

          5. Known allergy to any component of the study drug.

          6. Blood pressure &gt;180/110 (systolic above 180 OR diastolic above 110). If blood pressure
             is brought below 180/110 by anti-hypertensive treatment, individual can become
             eligible.

          7. Systemic anti-VEGF or pro-VEGF treatment within 4 months prior to randomization.

             These drugs should not be used during the study.

          8. For women of child-bearing potential: pregnant or lactating or intending to become
             pregnant within the next 24 months.

             (a) Women who are potential study participants should be questioned about the
             potential for pregnancy. Investigator judgment is used to determine when a pregnancy
             test is needed.

          9. Individual is expecting to move out of the area of the clinical center to an area not
             covered by another clinical center during the 24 months of the study.

        Individual has any of the following ocular characteristics:

          1. Macular edema is considered to be due to a cause other than DME.

             a) An eye should not be considered eligible if: (1) the macular edema is considered to
             be related to ocular surgery such as cataract extraction or (2) clinical exam and/or
             OCT suggest that vitreoretinal interface abnormalities (e.g., a taut posterior hyaloid
             or epiretinal membrane) are contributing to the macular edema.

          2. An ocular condition is present such that, in the opinion of the investigator, any
             visual acuity loss would not improve from resolution of macular edema (e.g., foveal
             atrophy, pigment abnormalities, dense subfoveal hard exudates, nonretinal condition).

          3. An ocular condition is present (other than DME) that, in the opinion of the
             investigator, might affect macular edema or alter visual acuity during the course of
             the study (e.g., vein occlusion, uveitis or other ocular inflammatory disease,
             neovascular glaucoma, etc.).

          4. Cataract is present that, in the opinion of the investigator, may alter visual acuity
             during the course of the study.

          5. Any history of prior laser or other surgical, intravitreal, or peribulbar treatment
             for DME (such as focal/grid macular photocoagulation, intravitreal or peribulbar
             corticosteroids, or anti-VEGF).

          6. History of topical steroid or nonsteroidal anti-inflammatory drugs (NSAID) treatment
             within 30 days prior to randomization.

          7. History of intravitreal or peribulbar corticosteroid within 4 months prior to
             randomization for an ocular condition other than DME.

          8. Any history of or anticipated need for intravitreal anti-VEGF within the next 6 months
             for an ocular condition other than DME (e.g. choroidal neovascularization, central
             retinal vein occlusion, PDR).

          9. History of PRP within 4 months prior to randomization or anticipated need for PRP in
             the 6 months following randomization.

         10. Any history of vitrectomy.

         11. History of major ocular surgery (cataract extraction, scleral buckle, any intraocular
             surgery, etc.) within prior 4 months or anticipated within the next 6 months following
             randomization.

         12. History of YAG capsulotomy performed within 2 months prior to randomization.

         13. Aphakia.

         14. Exam evidence of external ocular infection, including conjunctivitis, chalazion, or
             significant blepharitis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carl Baker, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Paducah Retina Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adam Glassman, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jaeb Center for Health Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Retina and Vitreous Consultants</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Arizona Medical Center/Department of Ophthalmology</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85711</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jones Eye Institute/University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205-7199</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retinal Diagnostic Center</name>
      <address>
        <city>Campbell</city>
        <state>California</state>
        <zip>95008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loma Linda University Health Care, Dept. of Ophthalmology</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Coast Retina Center</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern California Desert Retina Consultants, MC</name>
      <address>
        <city>Palm Desert</city>
        <state>California</state>
        <zip>92211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Consultants of Southern California</name>
      <address>
        <city>Redlands</city>
        <state>California</state>
        <zip>92374</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retinal Consultants Medical Group, Inc.</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95841</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Retina Consultants</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bay Area Retina Associates</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retinal Consultants of Southern California Medical Group, Inc.</name>
      <address>
        <city>Westlake Village</city>
        <state>California</state>
        <zip>91361</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Group of New England</name>
      <address>
        <city>New London</city>
        <state>Connecticut</state>
        <zip>06320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New England Retina Associates</name>
      <address>
        <city>Norwich</city>
        <state>Connecticut</state>
        <zip>06360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Ophthalmic Research Institute</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida College of Med., Department of Ophthalmology</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Retina Consultants</name>
      <address>
        <city>Lakeland</city>
        <state>Florida</state>
        <zip>33805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Macula Specialists of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bascom Palmer Eye Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ocala Eye Retina Consultants</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34474</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Magruder Eye Institute</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fort Lauderdale Eye Institute</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Sight</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarasota Retina Institute</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Associates of Florida, P.A.</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory Eye Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeast Retina Center, P.C.</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marietta Eye Clinic</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Eye Group</name>
      <address>
        <city>Sandy Springs</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern Medical Faculty Foundation</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Illinois at Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NorthShore University HealthSystem</name>
      <address>
        <city>Glenview</city>
        <state>Illinois</state>
        <zip>60026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois Retina Associates</name>
      <address>
        <city>Joliet</city>
        <state>Illinois</state>
        <zip>60435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Retina and Macula Associates</name>
      <address>
        <city>Oak Forest</city>
        <state>Illinois</state>
        <zip>60452</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carle Foundation Hospital</name>
      <address>
        <city>Urbana</city>
        <state>Illinois</state>
        <zip>61801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Raj Maturi</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John-Kenyon American Eye Institute</name>
      <address>
        <city>New Albany</city>
        <state>Indiana</state>
        <zip>47150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Associates Clinic, P.C.</name>
      <address>
        <city>Dubuque</city>
        <state>Iowa</state>
        <zip>52002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wolfe Eye Clinic</name>
      <address>
        <city>West Des Moines</city>
        <state>Iowa</state>
        <zip>50266</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center, Dept. of Ophthalmology</name>
      <address>
        <city>Prairie Village</city>
        <state>Kansas</state>
        <zip>66208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Associates, P.A.</name>
      <address>
        <city>Shawnee Mission</city>
        <state>Kansas</state>
        <zip>66204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina and Vitreous Associates of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paducah Retinal Center</name>
      <address>
        <city>Paducah</city>
        <state>Kentucky</state>
        <zip>42001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elman Retina Group, P.A.</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilmer Eye Institute at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287-9277</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joslin Diabetes Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vitreo-Retinal Associates, PC</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kellogg Eye Center, University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System, Dept of Ophthalmology and Eye Care Services</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Vitreous Center</name>
      <address>
        <city>Grand Blanc</city>
        <state>Michigan</state>
        <zip>48439</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Specialists of Michigan</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49525</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vitreo-Retinal Associates</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49546</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Andersen Eye Associates</name>
      <address>
        <city>Saginaw</city>
        <state>Michigan</state>
        <zip>48603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Center, PA</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Department of Ophthalmology</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid-America Retina Consultants, P.A.</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Retina Institute</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eyesight Ophthalmic Services, PA</name>
      <address>
        <city>Portsmouth</city>
        <state>New Hampshire</state>
        <zip>03801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Institute of Ophthalmology and Visual Science (IOVS)</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retinal and Ophthalmic Consultants, PC</name>
      <address>
        <city>Northfield</city>
        <state>New Jersey</state>
        <zip>08225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye Associates of New Mexico</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ross Eye Institute, SUNY Buffalo</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The New York Eye and Ear Infirmary/Faculty Eye Practice</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MaculaCare</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Associates of Western New York</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina-Vitreous Surgeons of Central New York, PC</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Carolina Retinal Associates, PA</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charlotte Eye, Ear, Nose and Throat Assoc., PA</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Associates of Cleveland, Inc.</name>
      <address>
        <city>Beachwood</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Vitreous Center</name>
      <address>
        <city>Edmond</city>
        <state>Oklahoma</state>
        <zip>73013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Retina, LLP</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Northwest, PC</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Casey Eye Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Eye Group</name>
      <address>
        <city>Lancaster</city>
        <state>Pennsylvania</state>
        <zip>17601-2644</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Vitreous Consultants</name>
      <address>
        <city>Monroeville</city>
        <state>Pennsylvania</state>
        <zip>15146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Scheie Eye Institute</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Retina Center</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29223</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palmetto Retina Center</name>
      <address>
        <city>West Columbia</city>
        <state>South Carolina</state>
        <zip>29169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeastern Retina Associates</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37421</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeastern Retina Associates, PC</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeastern Retina Associates, P.C.</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest Retina Specialists</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Retina Associates</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Research Center</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina and Vitreous of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Eye Physicians and Surgeons</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Consultants of Houston, PA</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Retina Associates</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79424</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valley Retina Institute</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retinal Consultants of San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Associates of Utah, P.C.</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Institute of Virginia</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University, Dept. of Ophthalmology</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spokane Eye Clinic</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin-Madison, Dept of Ophthalmology/Retina Service</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alberta Retina Consultants</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5H 0X5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Health Network - Toronto Western Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 258</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UBC/VCHA Eye Care Centre</name>
      <address>
        <city>Vancouver</city>
        <zip>V5Z 3N9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Baker CW, Glassman AR, Beaulieu WT, Antoszyk AN, Browning DJ, Chalam KV, Grover S, Jampol LM, Jhaveri CD, Melia M, Stockdale CR, Martin DF, Sun JK; DRCR Retina Network. Effect of Initial Management With Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss Among Patients With Diabetic Macular Edema Involving the Center of the Macula and Good Visual Acuity: A Randomized Clinical Trial. JAMA. 2019 May 21;321(19):1880-1894. doi: 10.1001/jama.2019.5790.</citation>
    <PMID>31037289</PMID>
  </results_reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>July 23, 2013</study_first_submitted>
  <study_first_submitted_qc>July 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2013</study_first_posted>
  <results_first_submitted>September 11, 2019</results_first_submitted>
  <results_first_submitted_qc>December 16, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 3, 2020</results_first_posted>
  <last_update_submitted>January 29, 2020</last_update_submitted>
  <last_update_submitted_qc>January 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetic Macular Edema</keyword>
  <keyword>anti-vascular endothelial growth factor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 18, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/91/NCT01909791/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 27, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/91/NCT01909791/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Initiation With Aflibercept</title>
          <description>Intravitreal aflibercept at baseline and every 4 weeks as needed (deferred laser may be added to intravitreal aflibercept if certain criteria are met)
Prompt aflibercept: Intravitreal injection of 2.0mg aflibercept performed on the day of randomization and up to every 4 weeks using defined treatment criteria
Deferred laser: Focal/grid laser is initiated while receiving anti-VEGF injections only if certain criteria are met</description>
        </group>
        <group group_id="P2">
          <title>Initiation With Laser Photocoagulation</title>
          <description>Focal/grid laser followed by intravitreal aflibercept if vision worsens
Prompt Laser: Focal/grid laser performed at baseline and as needed during follow-up
Deferred aflibercept: Intravitreal injection of 2.0mg aflibercept performed once certain criteria for vision loss are met and then up to every 4 weeks using defined treatment criteria</description>
        </group>
        <group group_id="P3">
          <title>Initiation With Observation</title>
          <description>No treatment to start followed by intravitreal aflibercept if vision worsens (deferred laser may be added to intravitreal aflibercept if certain criteria are met)
Deferred laser: Focal/grid laser is initiated while receiving anti-VEGF injections only if certain criteria are met
Deferred aflibercept: Intravitreal injection of 2.0mg aflibercept performed once certain criteria for vision loss are met and then up to every 4 weeks using defined treatment criteria</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="226"/>
                <participants group_id="P2" count="240"/>
                <participants group_id="P3" count="236"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="205"/>
                <participants group_id="P2" count="212"/>
                <participants group_id="P3" count="208"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="28"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missed Visit</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Initiation With Aflibercept</title>
          <description>Intravitreal aflibercept at baseline and every 4 weeks as needed (deferred laser may be added to intravitreal aflibercept if certain criteria are met)
Prompt aflibercept: Intravitreal injection of 2.0mg aflibercept performed on the day of randomization and up to every 4 weeks using defined treatment criteria
Deferred laser: Focal/grid laser is initiated while receiving anti-VEGF injections only if certain criteria are met</description>
        </group>
        <group group_id="B2">
          <title>Initiation With Laser Photocoagulation</title>
          <description>Focal/grid laser followed by intravitreal aflibercept if vision worsens
Prompt Laser: Focal/grid laser performed at baseline and as needed during follow-up
Deferred aflibercept: Intravitreal injection of 2.0mg aflibercept performed once certain criteria for vision loss are met and then up to every 4 weeks using defined treatment criteria</description>
        </group>
        <group group_id="B3">
          <title>Initiation With Observation</title>
          <description>No treatment to start followed by intravitreal aflibercept if vision worsens (deferred laser may be added to intravitreal aflibercept if certain criteria are met)
Deferred laser: Focal/grid laser is initiated while receiving anti-VEGF injections only if certain criteria are met
Deferred aflibercept: Intravitreal injection of 2.0mg aflibercept performed once certain criteria for vision loss are met and then up to every 4 weeks using defined treatment criteria</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="226"/>
            <count group_id="B2" value="240"/>
            <count group_id="B3" value="236"/>
            <count group_id="B4" value="702"/>
          </count_list>
        </analyzed>
        <analyzed>
          <units>Eyes</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="226"/>
            <count group_id="B2" value="240"/>
            <count group_id="B3" value="236"/>
            <count group_id="B4" value="702"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="226"/>
                <count group_id="B2" value="240"/>
                <count group_id="B3" value="236"/>
                <count group_id="B4" value="702"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="226"/>
                <count group_id="B2" value="240"/>
                <count group_id="B3" value="236"/>
                <count group_id="B4" value="702"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59" lower_limit="52" upper_limit="65"/>
                    <measurement group_id="B2" value="60" lower_limit="53" upper_limit="66"/>
                    <measurement group_id="B3" value="60" lower_limit="53" upper_limit="67"/>
                    <measurement group_id="B4" value="60" lower_limit="52" upper_limit="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="226"/>
                <count group_id="B2" value="240"/>
                <count group_id="B3" value="236"/>
                <count group_id="B4" value="702"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="226"/>
                <count group_id="B2" value="240"/>
                <count group_id="B3" value="236"/>
                <count group_id="B4" value="702"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="87"/>
                    <measurement group_id="B4" value="264"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="131"/>
                    <measurement group_id="B2" value="158"/>
                    <measurement group_id="B3" value="149"/>
                    <measurement group_id="B4" value="438"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="226"/>
                <count group_id="B2" value="240"/>
                <count group_id="B3" value="236"/>
                <count group_id="B4" value="702"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="226"/>
                <count group_id="B2" value="240"/>
                <count group_id="B3" value="236"/>
                <count group_id="B4" value="702"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Race/ethnicity</title>
              <category_list>
                <category>
                  <title>Non-Hispanic White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="145"/>
                    <measurement group_id="B2" value="160"/>
                    <measurement group_id="B3" value="161"/>
                    <measurement group_id="B4" value="466"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-Hispanic Black/African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="114"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="91"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>American Indian or Alaskan Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or not reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="226"/>
                <count group_id="B2" value="240"/>
                <count group_id="B3" value="236"/>
                <count group_id="B4" value="702"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="226"/>
                <count group_id="B2" value="240"/>
                <count group_id="B3" value="236"/>
                <count group_id="B4" value="702"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="225"/>
                    <measurement group_id="B2" value="238"/>
                    <measurement group_id="B3" value="232"/>
                    <measurement group_id="B4" value="695"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes type</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="226"/>
                <count group_id="B2" value="240"/>
                <count group_id="B3" value="236"/>
                <count group_id="B4" value="702"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="226"/>
                <count group_id="B2" value="240"/>
                <count group_id="B3" value="236"/>
                <count group_id="B4" value="702"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Type 2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="211"/>
                    <measurement group_id="B2" value="221"/>
                    <measurement group_id="B3" value="210"/>
                    <measurement group_id="B4" value="642"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Type 1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Uncertain</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of diabetes</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="226"/>
                <count group_id="B2" value="240"/>
                <count group_id="B3" value="236"/>
                <count group_id="B4" value="702"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="226"/>
                <count group_id="B2" value="240"/>
                <count group_id="B3" value="236"/>
                <count group_id="B4" value="702"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15" lower_limit="10" upper_limit="21"/>
                    <measurement group_id="B2" value="15" lower_limit="10" upper_limit="20"/>
                    <measurement group_id="B3" value="16" lower_limit="10" upper_limit="24"/>
                    <measurement group_id="B4" value="15" lower_limit="10" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Insulin used</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="226"/>
                <count group_id="B2" value="240"/>
                <count group_id="B3" value="236"/>
                <count group_id="B4" value="702"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="226"/>
                <count group_id="B2" value="240"/>
                <count group_id="B3" value="236"/>
                <count group_id="B4" value="702"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="161"/>
                    <measurement group_id="B2" value="145"/>
                    <measurement group_id="B3" value="160"/>
                    <measurement group_id="B4" value="466"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemoglobin A1c</title>
          <population>Hemoglobin A1c was missing for 9,8, and 10 eyes in the initiation with aflibercept, initiation with laser photocoagulation, and initiation with observation groups, respectively.</population>
          <units>Hemoglobin A1c percentage</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="217"/>
                <count group_id="B2" value="232"/>
                <count group_id="B3" value="226"/>
                <count group_id="B4" value="675"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="226"/>
                <count group_id="B2" value="240"/>
                <count group_id="B3" value="236"/>
                <count group_id="B4" value="702"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.6" lower_limit="6.8" upper_limit="9.1"/>
                    <measurement group_id="B2" value="7.6" lower_limit="6.6" upper_limit="8.6"/>
                    <measurement group_id="B3" value="7.6" lower_limit="6.8" upper_limit="8.7"/>
                    <measurement group_id="B4" value="7.6" lower_limit="6.7" upper_limit="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Arterial blood pressure</title>
          <units>mmHg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="226"/>
                <count group_id="B2" value="240"/>
                <count group_id="B3" value="236"/>
                <count group_id="B4" value="702"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="226"/>
                <count group_id="B2" value="240"/>
                <count group_id="B3" value="236"/>
                <count group_id="B4" value="702"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="99" lower_limit="91" upper_limit="107"/>
                    <measurement group_id="B2" value="98" lower_limit="89" upper_limit="105"/>
                    <measurement group_id="B3" value="98" lower_limit="91" upper_limit="105"/>
                    <measurement group_id="B4" value="98" lower_limit="90" upper_limit="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior myocardial infarction</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="226"/>
                <count group_id="B2" value="240"/>
                <count group_id="B3" value="236"/>
                <count group_id="B4" value="702"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="226"/>
                <count group_id="B2" value="240"/>
                <count group_id="B3" value="236"/>
                <count group_id="B4" value="702"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior stroke</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="226"/>
                <count group_id="B2" value="240"/>
                <count group_id="B3" value="236"/>
                <count group_id="B4" value="702"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="226"/>
                <count group_id="B2" value="240"/>
                <count group_id="B3" value="236"/>
                <count group_id="B4" value="702"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index</title>
          <description>Calculated as weight in kilograms divided by height in meters squared</description>
          <population>Missing for 42, 33, and 37 participants in the aflibercept, laser and observation groups, respectively.</population>
          <units>kg/m^2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="184"/>
                <count group_id="B2" value="207"/>
                <count group_id="B3" value="199"/>
                <count group_id="B4" value="590"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="226"/>
                <count group_id="B2" value="240"/>
                <count group_id="B3" value="236"/>
                <count group_id="B4" value="702"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.3" lower_limit="27.6" upper_limit="37.0"/>
                    <measurement group_id="B2" value="32.1" lower_limit="28.2" upper_limit="37.4"/>
                    <measurement group_id="B3" value="32.3" lower_limit="28.0" upper_limit="37.5"/>
                    <measurement group_id="B4" value="32.2" lower_limit="28.0" upper_limit="37.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Daily cigarette smoking</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="226"/>
                <count group_id="B2" value="240"/>
                <count group_id="B3" value="236"/>
                <count group_id="B4" value="702"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="226"/>
                <count group_id="B2" value="240"/>
                <count group_id="B3" value="236"/>
                <count group_id="B4" value="702"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Never</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="165"/>
                    <measurement group_id="B2" value="157"/>
                    <measurement group_id="B3" value="141"/>
                    <measurement group_id="B4" value="463"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prior</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="75"/>
                    <measurement group_id="B4" value="188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Current</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Recent or planned diabetic macular edema treatment in non-study eye</title>
          <units>Eyes</units>
          <param>Count of Units</param>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="226"/>
                <count group_id="B2" value="240"/>
                <count group_id="B3" value="236"/>
                <count group_id="B4" value="702"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="226"/>
                <count group_id="B2" value="240"/>
                <count group_id="B3" value="236"/>
                <count group_id="B4" value="702"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="92"/>
                    <measurement group_id="B4" value="268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior treatment for diabetic macular edema</title>
          <units>Eyes</units>
          <param>Count of Units</param>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="226"/>
                <count group_id="B2" value="240"/>
                <count group_id="B3" value="236"/>
                <count group_id="B4" value="702"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="226"/>
                <count group_id="B2" value="240"/>
                <count group_id="B3" value="236"/>
                <count group_id="B4" value="702"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior anti-VEGF for diabetic macular edema</title>
          <units>Eyes</units>
          <param>Count of Units</param>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="226"/>
                <count group_id="B2" value="240"/>
                <count group_id="B3" value="236"/>
                <count group_id="B4" value="702"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="226"/>
                <count group_id="B2" value="240"/>
                <count group_id="B3" value="236"/>
                <count group_id="B4" value="702"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior focal/grid laser photocoagulation for diabetic macular edema</title>
          <units>Eyes</units>
          <param>Count of Units</param>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="226"/>
                <count group_id="B2" value="240"/>
                <count group_id="B3" value="236"/>
                <count group_id="B4" value="702"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="226"/>
                <count group_id="B2" value="240"/>
                <count group_id="B3" value="236"/>
                <count group_id="B4" value="702"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior panretinal photocoagulation</title>
          <units>Eyes</units>
          <param>Count of Units</param>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="226"/>
                <count group_id="B2" value="240"/>
                <count group_id="B3" value="236"/>
                <count group_id="B4" value="702"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="226"/>
                <count group_id="B2" value="240"/>
                <count group_id="B3" value="236"/>
                <count group_id="B4" value="702"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lens status at clinical examination</title>
          <units>Eyes</units>
          <param>Count of Units</param>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="226"/>
                <count group_id="B2" value="240"/>
                <count group_id="B3" value="236"/>
                <count group_id="B4" value="702"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="226"/>
                <count group_id="B2" value="240"/>
                <count group_id="B3" value="236"/>
                <count group_id="B4" value="702"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Phakic (natural lens)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="180"/>
                    <measurement group_id="B2" value="188"/>
                    <measurement group_id="B3" value="182"/>
                    <measurement group_id="B4" value="550"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prosthetic intraocular lens</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="54"/>
                    <measurement group_id="B4" value="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>E-ETDRS visual acuity letter score</title>
          <description>Average of screening and randomization values. Best-corrected visual acuity following protocol-defined refraction. Visual Acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study (E-ETDRS) visual acuity test on a scale from 100 letters (Snellen equivalent of 20/12) to 0 letters (Snellen equivalent of 20/800).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="226"/>
                <count group_id="B2" value="240"/>
                <count group_id="B3" value="236"/>
                <count group_id="B4" value="702"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="226"/>
                <count group_id="B2" value="240"/>
                <count group_id="B3" value="236"/>
                <count group_id="B4" value="702"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85.2" spread="3.5"/>
                    <measurement group_id="B2" value="85.2" spread="3.8"/>
                    <measurement group_id="B3" value="85.2" spread="3.8"/>
                    <measurement group_id="B4" value="85.2" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Intraocular pressure</title>
          <units>mmHg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="226"/>
                <count group_id="B2" value="240"/>
                <count group_id="B3" value="236"/>
                <count group_id="B4" value="702"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="226"/>
                <count group_id="B2" value="240"/>
                <count group_id="B3" value="236"/>
                <count group_id="B4" value="702"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15" lower_limit="13" upper_limit="18"/>
                    <measurement group_id="B2" value="15" lower_limit="13" upper_limit="18"/>
                    <measurement group_id="B3" value="15" lower_limit="13" upper_limit="18"/>
                    <measurement group_id="B4" value="15" lower_limit="13" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patient-reported visual complaints presumed to be from diabetic macular edema</title>
          <units>Eyes</units>
          <param>Count of Units</param>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="226"/>
                <count group_id="B2" value="240"/>
                <count group_id="B3" value="236"/>
                <count group_id="B4" value="702"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="226"/>
                <count group_id="B2" value="240"/>
                <count group_id="B3" value="236"/>
                <count group_id="B4" value="702"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="99"/>
                    <measurement group_id="B2" value="116"/>
                    <measurement group_id="B3" value="118"/>
                    <measurement group_id="B4" value="333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Optical coherence tomography machine used to measure central subfield thickness</title>
          <description>An optical coherence tomography machine is the device that was used to measure the central subfield thickness.</description>
          <units>Eyes</units>
          <param>Count of Units</param>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="226"/>
                <count group_id="B2" value="240"/>
                <count group_id="B3" value="236"/>
                <count group_id="B4" value="702"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="226"/>
                <count group_id="B2" value="240"/>
                <count group_id="B3" value="236"/>
                <count group_id="B4" value="702"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Heidelberg Spectralis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="148"/>
                    <measurement group_id="B2" value="151"/>
                    <measurement group_id="B3" value="151"/>
                    <measurement group_id="B4" value="450"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Zeiss Cirrus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="89"/>
                    <measurement group_id="B3" value="85"/>
                    <measurement group_id="B4" value="252"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Central subfield thickness (time-domain equivalent)</title>
          <description>Calculated as the average of screening and randomization values.</description>
          <units>Microns</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="226"/>
                <count group_id="B2" value="240"/>
                <count group_id="B3" value="236"/>
                <count group_id="B4" value="702"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="226"/>
                <count group_id="B2" value="240"/>
                <count group_id="B3" value="236"/>
                <count group_id="B4" value="702"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="306" spread="55"/>
                    <measurement group_id="B2" value="314" spread="52"/>
                    <measurement group_id="B3" value="314" spread="64"/>
                    <measurement group_id="B4" value="311" spread="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Macular volume (time-domain equivalent)</title>
          <description>Average of screening and randomization values.</description>
          <population>missing for one participant in the observation group</population>
          <units>mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="226"/>
                <count group_id="B2" value="240"/>
                <count group_id="B3" value="236"/>
                <count group_id="B4" value="701"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="226"/>
                <count group_id="B2" value="240"/>
                <count group_id="B3" value="235"/>
                <count group_id="B4" value="701"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.9" spread="1.1"/>
                    <measurement group_id="B2" value="8.0" spread="1.2"/>
                    <measurement group_id="B3" value="8.0" spread="1.1"/>
                    <measurement group_id="B4" value="8.0" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetic retinopathy severity level</title>
          <description>Graded by a central reading center. PDR, proliferative diabetic retinopathy, NPDR, non-proliferative diabetic retinopathy</description>
          <population>Missing for 10, 13, and 7 eyes in the aflibercept, laser, and observation groups, respectively.</population>
          <units>Eyes</units>
          <param>Count of Units</param>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="226"/>
                <count group_id="B2" value="240"/>
                <count group_id="B3" value="236"/>
                <count group_id="B4" value="702"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="216"/>
                <count group_id="B2" value="227"/>
                <count group_id="B3" value="229"/>
                <count group_id="B4" value="672"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Diabetic Retinopathy absent or questionable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Microaneurysms only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild to moderate NPDR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="119"/>
                    <measurement group_id="B2" value="132"/>
                    <measurement group_id="B3" value="142"/>
                    <measurement group_id="B4" value="393"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately severe to severe NPDR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="62"/>
                    <measurement group_id="B4" value="184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inactive PDR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild to moderate PDR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Eyes With at Least 5-letter Decrease in E-ETDRS Visual Acuity Letter Score From Baseline</title>
        <description>Best-corrected visual acuity following protocol-defined refraction. Visual Acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study (E-ETDRS) visual acuity test on a scale from 100 letters (Snellen equivalent of 20/12) to 0 letters (Snellen equivalent of 20/800).</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Initiation With Aflibercept</title>
            <description>Intravitreal aflibercept at baseline and every 4 weeks as needed (deferred laser may be added to intravitreal aflibercept if certain criteria are met)
Prompt aflibercept: Intravitreal injection of 2.0mg aflibercept performed on the day of randomization and up to every 4 weeks using defined treatment criteria
Deferred laser: Focal/grid laser is initiated while receiving anti-VEGF injections only if certain criteria are met</description>
          </group>
          <group group_id="O2">
            <title>Initiation With Laser Photocoagulation</title>
            <description>Focal/grid laser followed by intravitreal aflibercept if vision worsens
Prompt Laser: Focal/grid laser performed at baseline and as needed during follow-up
Deferred aflibercept: Intravitreal injection of 2.0mg aflibercept performed once certain criteria for vision loss are met and then up to every 4 weeks using defined treatment criteria</description>
          </group>
          <group group_id="O3">
            <title>Initiation With Observation</title>
            <description>No treatment to start followed by intravitreal aflibercept if vision worsens (deferred laser may be added to intravitreal aflibercept if certain criteria are met)
Deferred laser: Focal/grid laser is initiated while receiving anti-VEGF injections only if certain criteria are met
Deferred aflibercept: Intravitreal injection of 2.0mg aflibercept performed once certain criteria for vision loss are met and then up to every 4 weeks using defined treatment criteria</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Eyes With at Least 5-letter Decrease in E-ETDRS Visual Acuity Letter Score From Baseline</title>
          <description>Best-corrected visual acuity following protocol-defined refraction. Visual Acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study (E-ETDRS) visual acuity test on a scale from 100 letters (Snellen equivalent of 20/12) to 0 letters (Snellen equivalent of 20/800).</description>
          <units>Eyes</units>
          <param>Count of Units</param>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="208"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="208"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Eyes With at Least 5-letter Increase or at Least 5-, 10-, or 15-letter Decrease in E-ETDRS Visual Acuity Letter Score From Baseline</title>
        <description>Best-corrected visual acuity following protocol-defined refraction. Visual Acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study (E-ETDRS) visual acuity test on a scale from 100 letters (Snellen equivalent of 20/12) to 0 letters (Snellen equivalent of 20/800).</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Initiation With Aflibercept</title>
            <description>Intravitreal aflibercept at baseline and every 4 weeks as needed (deferred laser may be added to intravitreal aflibercept if certain criteria are met)
Prompt aflibercept: Intravitreal injection of 2.0mg aflibercept performed on the day of randomization and up to every 4 weeks using defined treatment criteria
Deferred laser: Focal/grid laser is initiated while receiving anti-VEGF injections only if certain criteria are met</description>
          </group>
          <group group_id="O2">
            <title>Initiation With Laser Photocoagulation</title>
            <description>Focal/grid laser followed by intravitreal aflibercept if vision worsens
Prompt Laser: Focal/grid laser performed at baseline and as needed during follow-up
Deferred aflibercept: Intravitreal injection of 2.0mg aflibercept performed once certain criteria for vision loss are met and then up to every 4 weeks using defined treatment criteria</description>
          </group>
          <group group_id="O3">
            <title>Initiation With Observation</title>
            <description>No treatment to start followed by intravitreal aflibercept if vision worsens (deferred laser may be added to intravitreal aflibercept if certain criteria are met)
Deferred laser: Focal/grid laser is initiated while receiving anti-VEGF injections only if certain criteria are met
Deferred aflibercept: Intravitreal injection of 2.0mg aflibercept performed once certain criteria for vision loss are met and then up to every 4 weeks using defined treatment criteria</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Eyes With at Least 5-letter Increase or at Least 5-, 10-, or 15-letter Decrease in E-ETDRS Visual Acuity Letter Score From Baseline</title>
          <description>Best-corrected visual acuity following protocol-defined refraction. Visual Acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study (E-ETDRS) visual acuity test on a scale from 100 letters (Snellen equivalent of 20/12) to 0 letters (Snellen equivalent of 20/800).</description>
          <units>Eyes</units>
          <param>Count of Units</param>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="226"/>
                <count group_id="O3" value="220"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="226"/>
                <count group_id="O3" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>≥ 5-Letter Increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 5-Letter Decrease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 10-Letter Decrease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 15-Letter Decrease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in E-ETDRS Visual Acuity Letter Score From Baseline</title>
        <description>Best-corrected visual acuity following protocol-defined refraction. Visual Acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study (E-ETDRS) visual acuity test on a scale from 100 letters (Snellen equivalent of 20/12) to 0 letters (Snellen equivalent of 20/800).</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Initiation With Aflibercept</title>
            <description>Intravitreal aflibercept at baseline and every 4 weeks as needed (deferred laser may be added to intravitreal aflibercept if certain criteria are met)
Prompt aflibercept: Intravitreal injection of 2.0mg aflibercept performed on the day of randomization and up to every 4 weeks using defined treatment criteria
Deferred laser: Focal/grid laser is initiated while receiving anti-VEGF injections only if certain criteria are met</description>
          </group>
          <group group_id="O2">
            <title>Initiation With Laser Photocoagulation</title>
            <description>Focal/grid laser followed by intravitreal aflibercept if vision worsens
Prompt Laser: Focal/grid laser performed at baseline and as needed during follow-up
Deferred aflibercept: Intravitreal injection of 2.0mg aflibercept performed once certain criteria for vision loss are met and then up to every 4 weeks using defined treatment criteria</description>
          </group>
          <group group_id="O3">
            <title>Initiation With Observation</title>
            <description>No treatment to start followed by intravitreal aflibercept if vision worsens (deferred laser may be added to intravitreal aflibercept if certain criteria are met)
Deferred laser: Focal/grid laser is initiated while receiving anti-VEGF injections only if certain criteria are met
Deferred aflibercept: Intravitreal injection of 2.0mg aflibercept performed once certain criteria for vision loss are met and then up to every 4 weeks using defined treatment criteria</description>
          </group>
        </group_list>
        <measure>
          <title>Change in E-ETDRS Visual Acuity Letter Score From Baseline</title>
          <description>Best-corrected visual acuity following protocol-defined refraction. Visual Acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study (E-ETDRS) visual acuity test on a scale from 100 letters (Snellen equivalent of 20/12) to 0 letters (Snellen equivalent of 20/800).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="226"/>
                <count group_id="O3" value="220"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="226"/>
                <count group_id="O3" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="5.0"/>
                    <measurement group_id="O2" value="0.1" spread="5.5"/>
                    <measurement group_id="O3" value="0.0" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in E-ETDRS Visual Acuity Letter Score From Baseline Over 2 Years (Area Under the Curve)</title>
        <description>Best-corrected visual acuity following protocol-defined refraction. Visual Acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study (E-ETDRS) visual acuity test on a scale from 100 letters (Snellen equivalent of 20/12) to 0 letters (Snellen equivalent of 20/800). The area under the curve (units = letters·years) was divided by 2 years (units = years) to obtain an average change in letter score (units = letters) over the 2-year follow-up.</description>
        <time_frame>2 year</time_frame>
        <population>Best-corrected visual acuity letter score as measured by a certified tester using an electronic visual acuity testing machine based on the early treatment diabetic retinopathy study method . Best value on the scale 100, worst 0.</population>
        <group_list>
          <group group_id="O1">
            <title>Initial Aflibercept</title>
            <description>Intravitreal aflibercept at baseline and every 4 weeks as needed (deferred laser may be added to intravitreal aflibercept if certain criteria are met)
Prompt aflibercept: Intravitreal injection of 2.0mg aflibercept performed on the day of randomization and up to every 4 weeks using defined treatment criteria
Deferred laser: Focal/grid laser is initiated while receiving anti-VEGF injections only if certain criteria are met</description>
          </group>
          <group group_id="O2">
            <title>Initial Laser With Deferred Aflibercept if Needed</title>
            <description>Focal/grid laser followed by intravitreal aflibercept if vision worsens
Prompt Laser: Focal/grid laser performed at baseline and as needed during follow-up
Deferred aflibercept: Intravitreal injection of 2.0mg aflibercept performed once certain criteria for vision loss are met and then up to every 4 weeks using defined treatment criteria</description>
          </group>
          <group group_id="O3">
            <title>Observation</title>
            <description>No treatment to start followed by intravitreal aflibercept if vision worsens (deferred laser may be added to intravitreal aflibercept if certain criteria are met)
Deferred laser: Focal/grid laser is initiated while receiving anti-VEGF injections only if certain criteria are met
Deferred aflibercept: Intravitreal injection of 2.0mg aflibercept performed once certain criteria for vision loss are met and then up to every 4 weeks using defined treatment criteria</description>
          </group>
        </group_list>
        <measure>
          <title>Change in E-ETDRS Visual Acuity Letter Score From Baseline Over 2 Years (Area Under the Curve)</title>
          <description>Best-corrected visual acuity following protocol-defined refraction. Visual Acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study (E-ETDRS) visual acuity test on a scale from 100 letters (Snellen equivalent of 20/12) to 0 letters (Snellen equivalent of 20/800). The area under the curve (units = letters·years) was divided by 2 years (units = years) to obtain an average change in letter score (units = letters) over the 2-year follow-up.</description>
          <population>Best-corrected visual acuity letter score as measured by a certified tester using an electronic visual acuity testing machine based on the early treatment diabetic retinopathy study method . Best value on the scale 100, worst 0.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="208"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="208"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="4.0"/>
                    <measurement group_id="O2" value="0.0" spread="3.9"/>
                    <measurement group_id="O3" value="-0.4" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in OCT Central Subfield Thickness From Baseline</title>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Initial Aflibercept</title>
            <description>Intravitreal aflibercept at baseline and every 4 weeks as needed (deferred laser may be added to intravitreal aflibercept if certain criteria are met)
Prompt aflibercept: Intravitreal injection of 2.0mg aflibercept performed on the day of randomization and up to every 4 weeks using defined treatment criteria
Deferred laser: Focal/grid laser is initiated while receiving anti-VEGF injections only if certain criteria are met</description>
          </group>
          <group group_id="O2">
            <title>Initial Laser With Deferred Aflibercept if Needed</title>
            <description>Focal/grid laser followed by intravitreal aflibercept if vision worsens
Prompt Laser: Focal/grid laser performed at baseline and as needed during follow-up
Deferred aflibercept: Intravitreal injection of 2.0mg aflibercept performed once certain criteria for vision loss are met and then up to every 4 weeks using defined treatment criteria</description>
          </group>
          <group group_id="O3">
            <title>Observation</title>
            <description>No treatment to start followed by intravitreal aflibercept if vision worsens (deferred laser may be added to intravitreal aflibercept if certain criteria are met)
Deferred laser: Focal/grid laser is initiated while receiving anti-VEGF injections only if certain criteria are met
Deferred aflibercept: Intravitreal injection of 2.0mg aflibercept performed once certain criteria for vision loss are met and then up to every 4 weeks using defined treatment criteria</description>
          </group>
        </group_list>
        <measure>
          <title>Change in OCT Central Subfield Thickness From Baseline</title>
          <units>microns</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="207"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-48" spread="65"/>
                    <measurement group_id="O2" value="-41" spread="75"/>
                    <measurement group_id="O3" value="-42" spread="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Eyes With at Least 1 or 2 Logarithmic-step Central Subfield Thickness Improvement and Worsening</title>
        <description>Logarithmic transformation of optical coherence tomography central subfield thickness (CST) is calculated by taking the log base 10 of the ratio of the central subfield thickness divided by 200 and rounding to the nearest hundredth. The change is the change in the log values.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Initial Aflibercept</title>
            <description>Intravitreal aflibercept at baseline and every 4 weeks as needed (deferred laser may be added to intravitreal aflibercept if certain criteria are met)
Prompt aflibercept: Intravitreal injection of 2.0mg aflibercept performed on the day of randomization and up to every 4 weeks using defined treatment criteria
Deferred laser: Focal/grid laser is initiated while receiving anti-VEGF injections only if certain criteria are met</description>
          </group>
          <group group_id="O2">
            <title>Initial Laser With Deferred Aflibercept if Needed</title>
            <description>Focal/grid laser followed by intravitreal aflibercept if vision worsens
Prompt Laser: Focal/grid laser performed at baseline and as needed during follow-up
Deferred aflibercept: Intravitreal injection of 2.0mg aflibercept performed once certain criteria for vision loss are met and then up to every 4 weeks using defined treatment criteria</description>
          </group>
          <group group_id="O3">
            <title>Observation</title>
            <description>No treatment to start followed by intravitreal aflibercept if vision worsens (deferred laser may be added to intravitreal aflibercept if certain criteria are met)
Deferred laser: Focal/grid laser is initiated while receiving anti-VEGF injections only if certain criteria are met
Deferred aflibercept: Intravitreal injection of 2.0mg aflibercept performed once certain criteria for vision loss are met and then up to every 4 weeks using defined treatment criteria</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Eyes With at Least 1 or 2 Logarithmic-step Central Subfield Thickness Improvement and Worsening</title>
          <description>Logarithmic transformation of optical coherence tomography central subfield thickness (CST) is calculated by taking the log base 10 of the ratio of the central subfield thickness divided by 200 and rounding to the nearest hundredth. The change is the change in the log values.</description>
          <units>Eyes</units>
          <param>Count of Units</param>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="223"/>
                <count group_id="O3" value="220"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="223"/>
                <count group_id="O3" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>≥ 2 log-step CST decrease (improvement)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 1 log-step CST decrease (improvement)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 1 log-step CST increase (worsening)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 2 log-step CST increase (worsening)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Eyes With no Center-involved Diabetic Macular Edema and at Least 10% Central Subfield Thickness Decrease</title>
        <description>Center-involved diabetic macular edema defined as follows by central subfield thickness according to optical coherence tomography machine and sex: Heidelberg Spectralis ≥ 305 µm in women and ≥ 320 µm in men, and Zeiss Cirrus ≥ 290 µm in women and ≥ 305 µm in men.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Initial Aflibercept</title>
            <description>Intravitreal aflibercept at baseline and every 4 weeks as needed (deferred laser may be added to intravitreal aflibercept if certain criteria are met)
Prompt aflibercept: Intravitreal injection of 2.0mg aflibercept performed on the day of randomization and up to every 4 weeks using defined treatment criteria
Deferred laser: Focal/grid laser is initiated while receiving anti-VEGF injections only if certain criteria are met</description>
          </group>
          <group group_id="O2">
            <title>Initial Laser With Deferred Aflibercept if Needed</title>
            <description>Focal/grid laser followed by intravitreal aflibercept if vision worsens
Prompt Laser: Focal/grid laser performed at baseline and as needed during follow-up
Deferred aflibercept: Intravitreal injection of 2.0mg aflibercept performed once certain criteria for vision loss are met and then up to every 4 weeks using defined treatment criteria</description>
          </group>
          <group group_id="O3">
            <title>Observation</title>
            <description>No treatment to start followed by intravitreal aflibercept if vision worsens (deferred laser may be added to intravitreal aflibercept if certain criteria are met)
Deferred laser: Focal/grid laser is initiated while receiving anti-VEGF injections only if certain criteria are met
Deferred aflibercept: Intravitreal injection of 2.0mg aflibercept performed once certain criteria for vision loss are met and then up to every 4 weeks using defined treatment criteria</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Eyes With no Center-involved Diabetic Macular Edema and at Least 10% Central Subfield Thickness Decrease</title>
          <description>Center-involved diabetic macular edema defined as follows by central subfield thickness according to optical coherence tomography machine and sex: Heidelberg Spectralis ≥ 305 µm in women and ≥ 320 µm in men, and Zeiss Cirrus ≥ 290 µm in women and ≥ 305 µm in men.</description>
          <units>Eyes</units>
          <param>Count of Units</param>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="223"/>
                <count group_id="O3" value="220"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="223"/>
                <count group_id="O3" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="58"/>
                    <measurement group_id="O3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Number of Intraocular Injections of 2.0-mg Aflibercept Received Per Participant</title>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Initial Aflibercept</title>
            <description>Intravitreal aflibercept at baseline and every 4 weeks as needed (deferred laser may be added to intravitreal aflibercept if certain criteria are met)
Prompt aflibercept: Intravitreal injection of 2.0mg aflibercept performed on the day of randomization and up to every 4 weeks using defined treatment criteria
Deferred laser: Focal/grid laser is initiated while receiving anti-VEGF injections only if certain criteria are met</description>
          </group>
          <group group_id="O2">
            <title>Initial Laser With Deferred Aflibercept if Needed</title>
            <description>Focal/grid laser followed by intravitreal aflibercept if vision worsens
Prompt Laser: Focal/grid laser performed at baseline and as needed during follow-up
Deferred aflibercept: Intravitreal injection of 2.0mg aflibercept performed once certain criteria for vision loss are met and then up to every 4 weeks using defined treatment criteria</description>
          </group>
          <group group_id="O3">
            <title>Observation</title>
            <description>No treatment to start followed by intravitreal aflibercept if vision worsens (deferred laser may be added to intravitreal aflibercept if certain criteria are met)
Deferred laser: Focal/grid laser is initiated while receiving anti-VEGF injections only if certain criteria are met
Deferred aflibercept: Intravitreal injection of 2.0mg aflibercept performed once certain criteria for vision loss are met and then up to every 4 weeks using defined treatment criteria</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Number of Intraocular Injections of 2.0-mg Aflibercept Received Per Participant</title>
          <units>Injections</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="226"/>
                <count group_id="O3" value="220"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="226"/>
                <count group_id="O3" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" spread="2.5"/>
                    <measurement group_id="O2" value="0.7" spread="2.1"/>
                    <measurement group_id="O3" value="1.4" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Eyes With ≥ 2-step Worsening of Diabetic Retinopathy</title>
        <description>Includes eyes with baseline severity level of 75 (high-risk proliferative diabetic retinopathy) or less based on reading center grading of color fundus photographs using the Early Treatment Diabetic Retinopathy Study severity scale.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Initial Aflibercept</title>
            <description>Intravitreal aflibercept at baseline and every 4 weeks as needed (deferred laser may be added to intravitreal aflibercept if certain criteria are met)
Prompt aflibercept: Intravitreal injection of 2.0mg aflibercept performed on the day of randomization and up to every 4 weeks using defined treatment criteria
Deferred laser: Focal/grid laser is initiated while receiving anti-VEGF injections only if certain criteria are met</description>
          </group>
          <group group_id="O2">
            <title>Initial Laser With Deferred Aflibercept if Needed</title>
            <description>Focal/grid laser followed by intravitreal aflibercept if vision worsens
Prompt Laser: Focal/grid laser performed at baseline and as needed during follow-up
Deferred aflibercept: Intravitreal injection of 2.0mg aflibercept performed once certain criteria for vision loss are met and then up to every 4 weeks using defined treatment criteria</description>
          </group>
          <group group_id="O3">
            <title>Observation</title>
            <description>No treatment to start followed by intravitreal aflibercept if vision worsens (deferred laser may be added to intravitreal aflibercept if certain criteria are met)
Deferred laser: Focal/grid laser is initiated while receiving anti-VEGF injections only if certain criteria are met
Deferred aflibercept: Intravitreal injection of 2.0mg aflibercept performed once certain criteria for vision loss are met and then up to every 4 weeks using defined treatment criteria</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Eyes With ≥ 2-step Worsening of Diabetic Retinopathy</title>
          <description>Includes eyes with baseline severity level of 75 (high-risk proliferative diabetic retinopathy) or less based on reading center grading of color fundus photographs using the Early Treatment Diabetic Retinopathy Study severity scale.</description>
          <units>Eyes</units>
          <param>Count of Units</param>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="185"/>
                <count group_id="O2" value="187"/>
                <count group_id="O3" value="188"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="185"/>
                <count group_id="O2" value="187"/>
                <count group_id="O3" value="188"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>For Eyes Randomized to Initial Laser Photocoagulation and Initial Observation Groups, the Percentage Receiving Aflibercept Treatment</title>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Initiation With Laser Photocoagulation</title>
            <description>Focal/grid laser followed by intravitreal aflibercept if vision worsens
Prompt Laser: Focal/grid laser performed at baseline and as needed during follow-up
Deferred aflibercept: Intravitreal injection of 2.0mg aflibercept performed once certain criteria for vision loss are met and then up to every 4 weeks using defined treatment criteria</description>
          </group>
          <group group_id="O2">
            <title>Initiation With Observation</title>
            <description>No treatment to start followed by intravitreal aflibercept if vision worsens (deferred laser may be added to intravitreal aflibercept if certain criteria are met)
Deferred laser: Focal/grid laser is initiated while receiving anti-VEGF injections only if certain criteria are met
Deferred aflibercept: Intravitreal injection of 2.0mg aflibercept performed once certain criteria for vision loss are met and then up to every 4 weeks using defined treatment criteria</description>
          </group>
        </group_list>
        <measure>
          <title>For Eyes Randomized to Initial Laser Photocoagulation and Initial Observation Groups, the Percentage Receiving Aflibercept Treatment</title>
          <units>Eyes</units>
          <param>Count of Units</param>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="240"/>
                <count group_id="O2" value="236"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="240"/>
                <count group_id="O2" value="236"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Eyes With at Least 5-, 10-, or 15-letter Decrease in E-ETDRS Visual Acuity Letter Score From Baseline</title>
        <description>Best-corrected visual acuity following protocol-defined refraction. Visual Acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study (E-ETDRS) visual acuity test on a scale from 100 letters (Snellen equivalent of 20/12) to 0 letters (Snellen equivalent of 20/800).</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Initiation With Aflibercept</title>
            <description>Intravitreal aflibercept at baseline and every 4 weeks as needed (deferred laser may be added to intravitreal aflibercept if certain criteria are met)
Prompt aflibercept: Intravitreal injection of 2.0mg aflibercept performed on the day of randomization and up to every 4 weeks using defined treatment criteria
Deferred laser: Focal/grid laser is initiated while receiving anti-VEGF injections only if certain criteria are met</description>
          </group>
          <group group_id="O2">
            <title>Initiation With Laser Photocoagulation</title>
            <description>Focal/grid laser followed by intravitreal aflibercept if vision worsens
Prompt Laser: Focal/grid laser performed at baseline and as needed during follow-up
Deferred aflibercept: Intravitreal injection of 2.0mg aflibercept performed once certain criteria for vision loss are met and then up to every 4 weeks using defined treatment criteria</description>
          </group>
          <group group_id="O3">
            <title>Initiation With Observation</title>
            <description>No treatment to start followed by intravitreal aflibercept if vision worsens (deferred laser may be added to intravitreal aflibercept if certain criteria are met)
Deferred laser: Focal/grid laser is initiated while receiving anti-VEGF injections only if certain criteria are met
Deferred aflibercept: Intravitreal injection of 2.0mg aflibercept performed once certain criteria for vision loss are met and then up to every 4 weeks using defined treatment criteria</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Eyes With at Least 5-, 10-, or 15-letter Decrease in E-ETDRS Visual Acuity Letter Score From Baseline</title>
          <description>Best-corrected visual acuity following protocol-defined refraction. Visual Acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study (E-ETDRS) visual acuity test on a scale from 100 letters (Snellen equivalent of 20/12) to 0 letters (Snellen equivalent of 20/800).</description>
          <units>Eyes</units>
          <param>Count of Units</param>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="208"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="208"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>≥ 5-Letter Improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="53"/>
                    <measurement group_id="O3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 10-Letter Worsening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 15-Letter Worsening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in E-ETDRS Visual Acuity Letter Score From Baseline</title>
        <description>Best-corrected visual acuity following protocol-defined refraction. Visual Acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study (E-ETDRS) visual acuity test on a scale from 100 letters (Snellen equivalent of 20/12) to 0 letters (Snellen equivalent of 20/800).</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Initiation With Aflibercept</title>
            <description>Intravitreal aflibercept at baseline and every 4 weeks as needed (deferred laser may be added to intravitreal aflibercept if certain criteria are met)
Prompt aflibercept: Intravitreal injection of 2.0mg aflibercept performed on the day of randomization and up to every 4 weeks using defined treatment criteria
Deferred laser: Focal/grid laser is initiated while receiving anti-VEGF injections only if certain criteria are met</description>
          </group>
          <group group_id="O2">
            <title>Initiation With Laser Photocoagulation</title>
            <description>Focal/grid laser followed by intravitreal aflibercept if vision worsens
Prompt Laser: Focal/grid laser performed at baseline and as needed during follow-up
Deferred aflibercept: Intravitreal injection of 2.0mg aflibercept performed once certain criteria for vision loss are met and then up to every 4 weeks using defined treatment criteria</description>
          </group>
          <group group_id="O3">
            <title>Initiation With Observation</title>
            <description>No treatment to start followed by intravitreal aflibercept if vision worsens (deferred laser may be added to intravitreal aflibercept if certain criteria are met)
Deferred laser: Focal/grid laser is initiated while receiving anti-VEGF injections only if certain criteria are met
Deferred aflibercept: Intravitreal injection of 2.0mg aflibercept performed once certain criteria for vision loss are met and then up to every 4 weeks using defined treatment criteria</description>
          </group>
        </group_list>
        <measure>
          <title>Change in E-ETDRS Visual Acuity Letter Score From Baseline</title>
          <description>Best-corrected visual acuity following protocol-defined refraction. Visual Acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study (E-ETDRS) visual acuity test on a scale from 100 letters (Snellen equivalent of 20/12) to 0 letters (Snellen equivalent of 20/800).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="208"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="208"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="6.4"/>
                    <measurement group_id="O2" value="0.1" spread="6.3"/>
                    <measurement group_id="O3" value="-0.4" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in OCT Central Subfield Thickness From Baseline</title>
        <description>Measured using spectral-domain optical coherence tomography (OCT).</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Initial Aflibercept</title>
            <description>Intravitreal aflibercept at baseline and every 4 weeks as needed (deferred laser may be added to intravitreal aflibercept if certain criteria are met)
Prompt aflibercept: Intravitreal injection of 2.0mg aflibercept performed on the day of randomization and up to every 4 weeks using defined treatment criteria
Deferred laser: Focal/grid laser is initiated while receiving anti-VEGF injections only if certain criteria are met</description>
          </group>
          <group group_id="O2">
            <title>Initial Laser With Deferred Aflibercept if Needed</title>
            <description>Focal/grid laser followed by intravitreal aflibercept if vision worsens
Prompt Laser: Focal/grid laser performed at baseline and as needed during follow-up
Deferred aflibercept: Intravitreal injection of 2.0mg aflibercept performed once certain criteria for vision loss are met and then up to every 4 weeks using defined treatment criteria</description>
          </group>
          <group group_id="O3">
            <title>Observation</title>
            <description>No treatment to start followed by intravitreal aflibercept if vision worsens (deferred laser may be added to intravitreal aflibercept if certain criteria are met)
Deferred laser: Focal/grid laser is initiated while receiving anti-VEGF injections only if certain criteria are met
Deferred aflibercept: Intravitreal injection of 2.0mg aflibercept performed once certain criteria for vision loss are met and then up to every 4 weeks using defined treatment criteria</description>
          </group>
        </group_list>
        <measure>
          <title>Change in OCT Central Subfield Thickness From Baseline</title>
          <description>Measured using spectral-domain optical coherence tomography (OCT).</description>
          <units>microns</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="223"/>
                <count group_id="O3" value="220"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="223"/>
                <count group_id="O3" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-50" spread="55"/>
                    <measurement group_id="O2" value="-30" spread="69"/>
                    <measurement group_id="O3" value="-25" spread="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Eyes With at Least 1 or 2 Logarithmic-step Central Subfield Thickness Improvement and Worsening</title>
        <description>Logarithmic transformation of optical coherence tomography central subfield thickness is calculated by taking the log base 10 of the ratio of the central subfield thickness divided by 200 and rounding to the nearest hundredth. The change is the change in the log values.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Initial Aflibercept</title>
            <description>Intravitreal aflibercept at baseline and every 4 weeks as needed (deferred laser may be added to intravitreal aflibercept if certain criteria are met)
Prompt aflibercept: Intravitreal injection of 2.0mg aflibercept performed on the day of randomization and up to every 4 weeks using defined treatment criteria
Deferred laser: Focal/grid laser is initiated while receiving anti-VEGF injections only if certain criteria are met</description>
          </group>
          <group group_id="O2">
            <title>Initial Laser With Deferred Aflibercept if Needed</title>
            <description>Focal/grid laser followed by intravitreal aflibercept if vision worsens
Prompt Laser: Focal/grid laser performed at baseline and as needed during follow-up
Deferred aflibercept: Intravitreal injection of 2.0mg aflibercept performed once certain criteria for vision loss are met and then up to every 4 weeks using defined treatment criteria</description>
          </group>
          <group group_id="O3">
            <title>Observation</title>
            <description>No treatment to start followed by intravitreal aflibercept if vision worsens (deferred laser may be added to intravitreal aflibercept if certain criteria are met)
Deferred laser: Focal/grid laser is initiated while receiving anti-VEGF injections only if certain criteria are met
Deferred aflibercept: Intravitreal injection of 2.0mg aflibercept performed once certain criteria for vision loss are met and then up to every 4 weeks using defined treatment criteria</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Eyes With at Least 1 or 2 Logarithmic-step Central Subfield Thickness Improvement and Worsening</title>
          <description>Logarithmic transformation of optical coherence tomography central subfield thickness is calculated by taking the log base 10 of the ratio of the central subfield thickness divided by 200 and rounding to the nearest hundredth. The change is the change in the log values.</description>
          <units>Eyes</units>
          <param>Count of Units</param>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="207"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>≥ 2 log-step CST decrease (improvement)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 1 log-step CST decrease (improvement)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="56"/>
                    <measurement group_id="O3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 1 log-step CST increase (worsening)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 2 log-step CST increase (worsening)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Eyes With no Center-involved Diabetic Macular Edema and at Least 10% Central Subfield Thickness Decrease</title>
        <description>Center-involved diabetic macular edema defined as follows by central subfield thickness according to optical coherence tomography machine and sex: Heidelberg Spectralis ≥ 305 µm in women and ≥ 320 µm in men, and Zeiss Cirrus ≥ 290 µm in women and ≥ 305 µm in men.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Initial Aflibercept</title>
            <description>Intravitreal aflibercept at baseline and every 4 weeks as needed (deferred laser may be added to intravitreal aflibercept if certain criteria are met)
Prompt aflibercept: Intravitreal injection of 2.0mg aflibercept performed on the day of randomization and up to every 4 weeks using defined treatment criteria
Deferred laser: Focal/grid laser is initiated while receiving anti-VEGF injections only if certain criteria are met</description>
          </group>
          <group group_id="O2">
            <title>Initial Laser With Deferred Aflibercept if Needed</title>
            <description>Focal/grid laser followed by intravitreal aflibercept if vision worsens
Prompt Laser: Focal/grid laser performed at baseline and as needed during follow-up
Deferred aflibercept: Intravitreal injection of 2.0mg aflibercept performed once certain criteria for vision loss are met and then up to every 4 weeks using defined treatment criteria</description>
          </group>
          <group group_id="O3">
            <title>Observation</title>
            <description>No treatment to start followed by intravitreal aflibercept if vision worsens (deferred laser may be added to intravitreal aflibercept if certain criteria are met)
Deferred laser: Focal/grid laser is initiated while receiving anti-VEGF injections only if certain criteria are met
Deferred aflibercept: Intravitreal injection of 2.0mg aflibercept performed once certain criteria for vision loss are met and then up to every 4 weeks using defined treatment criteria</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Eyes With no Center-involved Diabetic Macular Edema and at Least 10% Central Subfield Thickness Decrease</title>
          <description>Center-involved diabetic macular edema defined as follows by central subfield thickness according to optical coherence tomography machine and sex: Heidelberg Spectralis ≥ 305 µm in women and ≥ 320 µm in men, and Zeiss Cirrus ≥ 290 µm in women and ≥ 305 µm in men.</description>
          <units>Eyes</units>
          <param>Count of Units</param>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="207"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="90"/>
                    <measurement group_id="O3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Number of Focal/Grid Photocoagulation Sessions Performed Per Participant</title>
        <time_frame>2 years</time_frame>
        <population>The initial laser session was completed for all eyes in the initial laser group.</population>
        <group_list>
          <group group_id="O1">
            <title>Initial Aflibercept</title>
            <description>Intravitreal aflibercept at baseline and every 4 weeks as needed (deferred laser may be added to intravitreal aflibercept if certain criteria are met)
Prompt aflibercept: Intravitreal injection of 2.0mg aflibercept performed on the day of randomization and up to every 4 weeks using defined treatment criteria
Deferred laser: Focal/grid laser is initiated while receiving anti-VEGF injections only if certain criteria are met</description>
          </group>
          <group group_id="O2">
            <title>Initial Laser With Deferred Aflibercept if Needed</title>
            <description>Focal/grid laser followed by intravitreal aflibercept if vision worsens
Prompt Laser: Focal/grid laser performed at baseline and as needed during follow-up
Deferred aflibercept: Intravitreal injection of 2.0mg aflibercept performed once certain criteria for vision loss are met and then up to every 4 weeks using defined treatment criteria</description>
          </group>
          <group group_id="O3">
            <title>Observation</title>
            <description>No treatment to start followed by intravitreal aflibercept if vision worsens (deferred laser may be added to intravitreal aflibercept if certain criteria are met)
Deferred laser: Focal/grid laser is initiated while receiving anti-VEGF injections only if certain criteria are met
Deferred aflibercept: Intravitreal injection of 2.0mg aflibercept performed once certain criteria for vision loss are met and then up to every 4 weeks using defined treatment criteria</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Number of Focal/Grid Photocoagulation Sessions Performed Per Participant</title>
          <population>The initial laser session was completed for all eyes in the initial laser group.</population>
          <units>Focal/grid photocoagulation session</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="208"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="208"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.4"/>
                    <measurement group_id="O2" value="1.5" spread="0.9"/>
                    <measurement group_id="O3" value="0.0" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Eyes With ≥ 2-step Improvement of Diabetic Retinopathy</title>
        <description>Includes eyes with baseline severity level of 35 (mild non-proliferative diabetic retinopathy) or greater based on reading center grading of color fundus photographs using the Early Treatment Diabetic Retinopathy Study severity scale. Excludes eyes with severity level 60 at baseline since improvement is not possible in these eyes.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Initial Aflibercept</title>
            <description>Intravitreal aflibercept at baseline and every 4 weeks as needed (deferred laser may be added to intravitreal aflibercept if certain criteria are met)
Prompt aflibercept: Intravitreal injection of 2.0mg aflibercept performed on the day of randomization and up to every 4 weeks using defined treatment criteria
Deferred laser: Focal/grid laser is initiated while receiving anti-VEGF injections only if certain criteria are met</description>
          </group>
          <group group_id="O2">
            <title>Initial Laser With Deferred Aflibercept if Needed</title>
            <description>Focal/grid laser followed by intravitreal aflibercept if vision worsens
Prompt Laser: Focal/grid laser performed at baseline and as needed during follow-up
Deferred aflibercept: Intravitreal injection of 2.0mg aflibercept performed once certain criteria for vision loss are met and then up to every 4 weeks using defined treatment criteria</description>
          </group>
          <group group_id="O3">
            <title>Observation</title>
            <description>No treatment to start followed by intravitreal aflibercept if vision worsens (deferred laser may be added to intravitreal aflibercept if certain criteria are met)
Deferred laser: Focal/grid laser is initiated while receiving anti-VEGF injections only if certain criteria are met
Deferred aflibercept: Intravitreal injection of 2.0mg aflibercept performed once certain criteria for vision loss are met and then up to every 4 weeks using defined treatment criteria</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Eyes With ≥ 2-step Improvement of Diabetic Retinopathy</title>
          <description>Includes eyes with baseline severity level of 35 (mild non-proliferative diabetic retinopathy) or greater based on reading center grading of color fundus photographs using the Early Treatment Diabetic Retinopathy Study severity scale. Excludes eyes with severity level 60 at baseline since improvement is not possible in these eyes.</description>
          <units>Eyes</units>
          <param>Count of Units</param>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="170"/>
                <count group_id="O3" value="177"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="170"/>
                <count group_id="O3" value="177"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Number of Intraocular Injections of 2.0-mg Aflibercept Received Per Participant</title>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Initial Aflibercept</title>
            <description>Intravitreal aflibercept at baseline and every 4 weeks as needed (deferred laser may be added to intravitreal aflibercept if certain criteria are met)
Prompt aflibercept: Intravitreal injection of 2.0mg aflibercept performed on the day of randomization and up to every 4 weeks using defined treatment criteria
Deferred laser: Focal/grid laser is initiated while receiving anti-VEGF injections only if certain criteria are met</description>
          </group>
          <group group_id="O2">
            <title>Initial Laser With Deferred Aflibercept if Needed</title>
            <description>Focal/grid laser followed by intravitreal aflibercept if vision worsens
Prompt Laser: Focal/grid laser performed at baseline and as needed during follow-up
Deferred aflibercept: Intravitreal injection of 2.0mg aflibercept performed once certain criteria for vision loss are met and then up to every 4 weeks using defined treatment criteria</description>
          </group>
          <group group_id="O3">
            <title>Observation</title>
            <description>No treatment to start followed by intravitreal aflibercept if vision worsens (deferred laser may be added to intravitreal aflibercept if certain criteria are met)
Deferred laser: Focal/grid laser is initiated while receiving anti-VEGF injections only if certain criteria are met
Deferred aflibercept: Intravitreal injection of 2.0mg aflibercept performed once certain criteria for vision loss are met and then up to every 4 weeks using defined treatment criteria</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Number of Intraocular Injections of 2.0-mg Aflibercept Received Per Participant</title>
          <units>Injections</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="208"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="208"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" spread="4.2"/>
                    <measurement group_id="O2" value="2.1" spread="4.0"/>
                    <measurement group_id="O3" value="3.1" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 Years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Initiation With Laser Photocoagulation</title>
          <description>Focal/grid laser followed by intravitreal aflibercept if vision worsens
Prompt Laser: Focal/grid laser performed at baseline and as needed during follow-up
Deferred aflibercept: Intravitreal injection of 2.0mg aflibercept performed once certain criteria for vision loss are met and then up to every 4 weeks using defined treatment criteria</description>
        </group>
        <group group_id="E2">
          <title>Initiation With Observation</title>
          <description>No treatment to start followed by intravitreal aflibercept if vision worsens (deferred laser may be added to intravitreal aflibercept if certain criteria are met)
Deferred laser: Focal/grid laser is initiated while receiving anti-VEGF injections only if certain criteria are met
Deferred aflibercept: Intravitreal injection of 2.0mg aflibercept performed once certain criteria for vision loss are met and then up to every 4 weeks using defined treatment criteria</description>
        </group>
        <group group_id="E3">
          <title>Initiation With Aflibercept</title>
          <description>Intravitreal aflibercept at baseline and every 4 weeks as needed (deferred laser may be added to intravitreal aflibercept if certain criteria are met)
Prompt aflibercept: Intravitreal injection of 2.0mg aflibercept performed on the day of randomization and up to every 4 weeks using defined treatment criteria
Deferred laser: Focal/grid laser is initiated while receiving anti-VEGF injections only if certain criteria are met</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="77" subjects_at_risk="236"/>
                <counts group_id="E3" subjects_affected="69" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Anaemia of chronic disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Plasma cell myeloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="236"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Atrioventricular block first degree</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Bicuspid aortic valve</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="240"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="236"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Hypertensive heart disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="236"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Diabetic coma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract traumatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Rhegmatogenous retinal detachment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="240"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="236"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="240"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="240"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Back injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Compression fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Heat exhaustion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Blood electrolytes decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Blood glucose decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Vertebral foraminal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Carotid artery occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Hypoglycaemic encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="240"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Cardiorenal syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>End stage renal disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Nephropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="240"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="236"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="240"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Diabetic ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia repair</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Cardiac operation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Cardiac pacemaker insertion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Carpal tunnel decompression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Cholecystectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Coronary arterial stent insertion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Coronary artery bypass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Gastric banding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Gastric bypass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Hysterectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Implantable defibrillator insertion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Knee arthroplasty</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Knee operation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Leg amputation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Stent placement</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Surgery</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Toe amputation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Vascular graft</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Carotid artery disease</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="240"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="236"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="240"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Poor peripheral circulation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="194" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="197" subjects_at_risk="236"/>
                <counts group_id="E3" subjects_affected="185" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="240"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="236"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Anaemia of chronic disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Atrioventricular block first degree</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="240"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Long QT syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="240"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="236"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Mastoiditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Meniere's disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Tympanic membrane perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune thyroiditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="240"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="236"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="240"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="236"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Hyperparathyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="236"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Pituitary tumour benign</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Thyroid neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Age-related macular degeneration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Altered visual depth perception</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Amaurosis fugax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Angle closure glaucoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Asthenopia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Blepharitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="240"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Blepharospasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Borderline glaucoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="240"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="236"/>
                <counts group_id="E3" events="17" subjects_affected="17" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Cataract cortical</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="240"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="236"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Cataract nuclear</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Cataract subcapsular</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="240"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="236"/>
                <counts group_id="E3" events="13" subjects_affected="11" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Chalazion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Choroidal neovascularisation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="240"/>
                <counts group_id="E2" events="13" subjects_affected="9" subjects_at_risk="236"/>
                <counts group_id="E3" events="23" subjects_affected="17" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Conjunctival hyperaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="236"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Conjunctivitis allergic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Conjunctivitis viral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Corneal abrasion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="240"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Corneal defect</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Corneal disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Corneal dystrophy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Corneal erosion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Corneal oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Corneal opacity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Corneal pigmentation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Corneal scar</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Cystoid macular oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Diabetic retinal oedema</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="240"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="236"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Diabetic retinopathy</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="240"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="240"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="240"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="236"/>
                <counts group_id="E3" events="18" subjects_affected="17" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Eye discharge</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="240"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="236"/>
                <counts group_id="E3" events="13" subjects_affected="12" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="240"/>
                <counts group_id="E2" events="14" subjects_affected="11" subjects_at_risk="236"/>
                <counts group_id="E3" events="19" subjects_affected="16" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="240"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="236"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Eye swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Eyelid margin crusting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Eyelid oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Eyelid pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Eyelid ptosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Foreign body in eye</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Foreign body sensation in eyes</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="240"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="236"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Glare</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="240"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Hyalosis asteroid</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Hyphaema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Iris adhesions</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Iris neovascularisation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Iritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Keratitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Keratopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="240"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="236"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Macular degeneration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Macular fibrosis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Macular ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Macular oedema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Meibomian gland dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Metamorphopsia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="240"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Ocular discomfort</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="240"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="236"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="236"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Ocular hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Ophthalmic herpes simplex</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Optic atrophy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Optic ischaemic neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Optic nerve cupping</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="240"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="236"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Photopsia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="240"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="236"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Posterior capsule opacification</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Punctate keratitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="240"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Retinal aneurysm</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="240"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="236"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Retinal artery embolism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Retinal exudates</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="240"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="236"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Retinal haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="240"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="236"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Retinal ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Retinal neovascularisation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="240"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="236"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Retinal oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Retinal pigment epitheliopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Retinal tear</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="240"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Retinal vein occlusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Retinopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Retinopathy hypertensive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Rhegmatogenous retinal detachment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Subretinal fibrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Ulcerative keratitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="39" subjects_affected="31" subjects_at_risk="240"/>
                <counts group_id="E2" events="43" subjects_affected="34" subjects_at_risk="236"/>
                <counts group_id="E3" events="46" subjects_affected="40" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="240"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="236"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Visual field defect</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="240"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="236"/>
                <counts group_id="E3" events="11" subjects_affected="9" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Vitreous adhesions</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="236"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Vitreous detachment</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="240"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="236"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Vitreous disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Vitreous floaters</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="240"/>
                <counts group_id="E2" events="22" subjects_affected="21" subjects_at_risk="236"/>
                <counts group_id="E3" events="34" subjects_affected="27" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="240"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="236"/>
                <counts group_id="E3" events="11" subjects_affected="8" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Anal incontinence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Chronic gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="240"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Diabetic gastroparesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="240"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="236"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="240"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="236"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="240"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="236"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Gingival pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="240"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="236"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Salivary gland disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Tooth fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="240"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Tooth loss</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="240"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="236"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="240"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="236"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="240"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="236"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Injection site discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Injection site irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Local swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Necrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="240"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="236"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="240"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="240"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="236"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Non-alcoholic steatohepatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="240"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Systemic lupus erythematosus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Candida infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Escherichia infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Fungal skin infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Helicobacter infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="240"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="240"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="236"/>
                <counts group_id="E3" events="11" subjects_affected="10" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="240"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E3" events="10" subjects_affected="8" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Onychomycosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection fungal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Streptococcal infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Arthropod sting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Chemical injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="240"/>
                <counts group_id="E2" events="8" subjects_affected="5" subjects_at_risk="236"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="240"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Limb traumatic amputation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="236"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Biopsy skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Blood creatine increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Blood creatinine abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Blood glucose decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Blood lactic acid increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Blood testosterone decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Carotid bruit</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Echocardiogram abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Free prostate-specific antigen increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Glycosylated haemoglobin increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Heart rate irregular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Intraocular pressure increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Laboratory test abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="9" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Low density lipoprotein increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Protein urine present</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal loss of weight</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Abnormal weight gain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Fluid retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="240"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="236"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Iron deficiency</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="240"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Vitamin D deficiency</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="240"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="236"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Ankylosing spondylitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="240"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="236"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="240"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="236"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="240"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="236"/>
                <counts group_id="E3" events="10" subjects_affected="9" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Coccydynia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Dupuytren's contracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Exostosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="240"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="240"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="240"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Joint effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="240"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="236"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Musculoskeletal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="240"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="236"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="240"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="236"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Myokymia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Neuropathic arthropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Osteopenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="240"/>
                <counts group_id="E2" events="14" subjects_affected="11" subjects_at_risk="236"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Plantar fasciitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Polymyalgia rheumatica</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Stiff person syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Trigger finger</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="8" subjects_affected="4" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Abdominal neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Benign neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Hepatic cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Papilloma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Salivary gland neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Apraxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Autonomic neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Benign intracranial hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="240"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Cervical radiculopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Diabetic neuropathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="240"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="240"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="236"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Facial paralysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Head discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="240"/>
                <counts group_id="E2" events="16" subjects_affected="14" subjects_at_risk="236"/>
                <counts group_id="E3" events="17" subjects_affected="15" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Hemiplegia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="240"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Migraine with aura</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Myasthenia gravis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Nerve compression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Nerve injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="240"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Restless legs syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="240"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="236"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Ulnar nerve injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>VIIth nerve paralysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>VIth nerve paralysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="240"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="240"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="240"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="236"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="240"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="236"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Stress</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Acute prerenal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Anuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="240"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="240"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Diabetic nephropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="240"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Hypertonic bladder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Microalbuminuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Nephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Oliguria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="240"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="236"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Renal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="17" subjects_affected="13" subjects_at_risk="240"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="236"/>
                <counts group_id="E3" events="8" subjects_affected="6" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Breast cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Postmenopausal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Prostatomegaly</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Testicular disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="9" subjects_affected="4" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="240"/>
                <counts group_id="E2" events="19" subjects_affected="16" subjects_at_risk="236"/>
                <counts group_id="E3" events="10" subjects_affected="9" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="240"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="236"/>
                <counts group_id="E3" events="11" subjects_affected="8" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="240"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Hypercapnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="240"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="236"/>
                <counts group_id="E3" events="26" subjects_affected="23" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="240"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="236"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Respiratory tract congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="20" subjects_affected="13" subjects_at_risk="240"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="236"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="16" subjects_affected="13" subjects_at_risk="240"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="236"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Upper-airway cough syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="240"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Cutis laxa</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Dermal cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Dermatophytosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="240"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="236"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Diabetic ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="240"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Ingrowing nail</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="240"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Intertrigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Nail avulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Onychogryphosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="240"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="236"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Seborrhoeic dermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Skin bacterial infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Skin cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="240"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Skin disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="240"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="236"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Swelling face</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Arterial bypass operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Benign tumour excision</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Bile duct stent insertion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Blepharoplasty</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Carpal tunnel decompression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Cataract operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Cholecystectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Coronary arterial stent insertion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Dental implantation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Endodontic procedure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Hysterectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Knee operation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Metatarsal excision</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Retinal laser coagulation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Shoulder operation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Skin graft</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Skin lesion excision</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Spinal decompression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Stent placement</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Surgery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Tooth extraction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="240"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Transfusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Wrist surgery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriovenous fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Essential hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="240"/>
                <counts group_id="E2" events="20" subjects_affected="18" subjects_at_risk="236"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="240"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Poor peripheral circulation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Adam Glassman</name_or_title>
      <organization>Jaeb Center for Health Research</organization>
      <phone>8139758690</phone>
      <email>drcrnet@jaeb.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

